Halozyme Therapeutics (NASDAQ:HALO) stated gains of 390,590 shares or 1.9% in the short interest. The short interest registered from 20,316,904 on May 31,2016 to 20,707,494 on June 15,2016. In terms of floated shares, the shorted positions stood at 19.1%. The stock has been averaging 1,735,617 shares daily in trading and would need 12 days to cover the shorts. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Halozyme Therapeutics (NASDAQ:HALO): The stock opened at $8.71 on Friday but the bulls could not build on the opening and the stock topped out at $9.10 for the day. The stock traded down to $8.44 during the day, due to lack of any buying support eventually closed down at $8.44 with a loss of -8.16% for the day. The stock had closed at $9.19 on the previous day. The total traded volume was 2,171,373 shares.
The company shares have dropped -60.26% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $25.25 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $9.21 and the 200 Day Moving Average price is recorded at $10.54.
Halozyme Therapeutics (NASDAQ:HALO) has tumbled 0.94% during the past week and has dropped 15.6% in the last 4 week period. The company has outperformed the S&P 500 by 0.7% in the past week but underperformed the index by 13.05% in the last 4 weeks.
Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.